Holen Sie sich die Stockscreener-App
1.90
7.32%
-0.15
Handel nachbörslich:
1.93
0.03
+1.58%
Schlusskurs vom Vortag:
$2.05
Offen:
$2.07
24-Stunden-Volumen:
6.59M
Relative Volume:
0.93
Marktkapitalisierung:
$395.62M
Einnahmen:
$176.23M
Nettoeinkommen (Verlust:
$-257.83M
KGV:
-1.3103
EPS:
-1.45
Netto-Cashflow:
$-246.00M
1W Leistung:
-29.63%
1M Leistung:
+106.36%
6M Leistung:
+192.49%
1J Leistung:
+393.89%
1-Tages-Spanne:
$1.82
$2.17
1-Wochen-Bereich:
$1.82
$2.86
52-Wochen-Spanne:
$0.304
$3.179
Sangamo Therapeutics Inc Stock (SGMO) Company Profile
Firmenname
Sangamo Therapeutics Inc
Sektor
Branche
Telefon
(510) 970-6000
Adresse
501 CANAL BLVD., RICHMOND, CA
Vergleichen Sie SGMO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| SGMO | 1.90 | 395.62M | 176.23M | -257.83M | -246.00M | -1.45 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-04-28 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-02-27 | Hochstufung | Wedbush | Neutral → Outperform |
| 2023-01-06 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-06-13 | Fortgesetzt | Wedbush | Neutral |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-01-07 | Fortgesetzt | Guggenheim | Neutral |
| 2021-01-06 | Eingeleitet | Stifel | Hold |
| 2020-12-16 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-09-08 | Eingeleitet | BofA Securities | Buy |
| 2020-07-07 | Eingeleitet | SunTrust | Buy |
| 2019-08-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-11-14 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-11-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2018-10-10 | Eingeleitet | Guggenheim | Buy |
| 2018-06-20 | Eingeleitet | BofA/Merrill | Buy |
| 2017-11-15 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2017-06-22 | Fortgesetzt | Jefferies | Buy |
| 2016-11-01 | Herabstufung | Wedbush | Outperform → Neutral |
| 2016-10-19 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2015-12-04 | Eingeleitet | Wells Fargo | Outperform |
| 2015-10-23 | Fortgesetzt | Jefferies | Buy |
| 2013-05-03 | Eingeleitet | BioLogic Equity Research | Sell |
| 2011-02-23 | Bestätigt | JMP Securities | Mkt Outperform |
| 2010-07-29 | Bestätigt | Wedbush | Outperform |
| 2009-10-19 | Eingeleitet | Brean Murray | Sell |
| 2009-10-07 | Bestätigt | Leerink Swann | Outperform |
| 2009-08-25 | Bestätigt | JMP Securities | Mkt Outperform |
Alle ansehen
Sangamo Therapeutics Inc Aktie (SGMO) Neueste Nachrichten
Research Analysts Set Expectations for SGMO FY2024 Earnings - MarketBeat
FY2028 Earnings Forecast for SGMO Issued By HC Wainwright - MarketBeat
Sangamo Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
Sangamo Therapeutics (NASDAQ:SGMO) Price Target Raised to $9.00 at Barclays - MarketBeat
Sangamo Therapeutics' SWOT analysis: gene therapy firm's stock faces challenges, opportunities - Investing.com Canada
Sangamo: Q3 Earnings Snapshot - Marketscreener.com
Sangamo Therapeutics (SGMO) Tops Q3 Earnings and Revenue Estimates - MSN
Earnings call: Sangamo Therapeutics reports progress in gene therapies By Investing.com - Investing.com Australia
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Sangamo Therapeutics reports progress in gene therapies - Investing.com
Sangamo Therapeutics Inc (SGMO) Q3 2024 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
SGMOSangamo Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Sangamo Therapeutics Inc (SGMO) Q3 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Sangamo Therapeutics Q3 beats propel stock 5% higher - MSN
Sangamo Therapeutics earnings beat by $0.06, revenue topped estimates - Investing.com UK
Sangamo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Sangamo Stock Soars: FDA Fast-Tracks Fabry Therapy, Lands $50M Genentech Deal | SGMO Stock News - StockTitan
Sangamo Therapeutics's Earnings Outlook - Benzinga
FY2024 Earnings Forecast for SGMO Issued By HC Wainwright - Defense World
Gene Therapy Market to Grow by USD 6.74 Billion from 2024-2028, as Rise in Special Drug Designations Drives Demand with AI-Powered Market EvolutionTechnavio - The Malaysian Reserve
Equities Analysts Set Expectations for SGMO FY2024 Earnings - MarketBeat
Sangamo Therapeutics (NASDAQ:SGMO) Reaches New 12-Month High on Analyst Upgrade - Defense World
Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences - The Manila Times
Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences - GlobeNewswire Inc.
Sangamo (SGMO) Stock Rally Continues In Pre-Market Ahead of Financial Results Release - Stocks Telegraph
Sangamo Therapeutics (SGMO) Set to Announce Quarterly Earnings on Tuesday - MarketBeat
Sangamo Therapeutics (NASDAQ:SGMO) Price Target Raised to $10.00 at HC Wainwright - MarketBeat
Vanguard Group Inc's Strategic Reduction in Sangamo Therapeutics Inc - GuruFocus.com
Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast - StockTitan
individual investors who own 55% along with institutions invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) saw increase in their holdings value last week - Yahoo Finance
Sangamo Therapeutics (NASDAQ:SGMO) Stock Crosses Above 200 Day Moving Average – Here’s Why - Defense World
Sangamo Therapeutics (NASDAQ:SGMO) Stock Passes Above 200 Day Moving AverageWhat's Next? - MarketBeat
Gene Therapy Market Detailed Analysis and Forecast to 2031 - InsightAce Analytic
StockWatch: Sangamo Shares Surge on Shorter Pathway for Fabry Candidate - Genetic Engineering & Biotechnology News
Fabry disease gene therapy study data enough for FDA submission - Fabry Disease News
Prime Medicine Spat with Tessera Rumbles on at ESGCT - Genetic Engineering & Biotechnology News
Booz Allen Posts Upbeat Q3 Earnings, Joins Deckers Outdoor, Saia, Boyd Gaming And Other Big Stocks Moving Higher On FridayBooz Allen Hamilton (NYSE:BAH) - Benzinga
Sangamo Therapeutics' SWOT analysis: genomic medicine stock at crossroads - Investing.com
Sangamo Therapeutics' SWOT analysis: genomic medicine stock at crossroads By Investing.com - Investing.com UK
4 Analysts Have This To Say About Sangamo Therapeutics - Benzinga
What Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 26% Share Price Gain Is Not Telling You - Simply Wall St
Sangamo shares jump as FDA clears faster gene therapy pathway - The Pharma Letter
Sangamo stock rallies 37% on FDA update for Fabry disease drug - MSN
Sangamo Therapeutics, Cyclacel Pharma, GE Aerospace: 3 Stocks Retailers Are Most Bullish Tuesday Afternoon - Barchart
Sangamo Therapeutics (NASDAQ:SGMO) Stock Rating Reaffirmed by HC Wainwright - MarketBeat
Traders Purchase Large Volume of Call Options on Sangamo Therapeutics (NASDAQ:SGMO) - MarketBeat
Sangamo Therapeutics Shares Jump After FDA Discussion on Accelerated Approval Pathway for Fabry Disease Drug - MarketWatch
Sangamo stock rallies 37% on FDA update for Fabry disease drug (NASDAQ:SGMO) - Seeking Alpha
CBER’s lean into accelerated approval slashes three years from Sangamo gene therapy - BioCentury
Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025 - Business Wire
Sangamo Follow-Up: Giro-Vec And STAC-BBB? Check. Isa-Vec… Trifecta Soon? (NASDAQ:SGMO) - Seeking Alpha
Finanzdaten der Sangamo Therapeutics Inc-Aktie (SGMO)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):